UNSPSC 51373333: Belladonna/opium

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.

UNSPSC 51373333 Belladonna/opium, a Commodity-level code, does not align with the actual work being solicited under it by state and local bodies. Recent opportunities posted under this code involve naloxone procurement, therapeutic pharmacy initiatives, and generic multi-source pharmaceuticals—none of which are controlled opium derivatives or belladonna alkaloids. The mismatch suggests either a classification error in the posting systems or that the code is being used as a catch-all placeholder for pharmaceutical procurement without regard to its nominal scope. State and local buyers—including county health departments, state health and human services agencies, and cooperative purchasing alliances—are using it to solicit opioid-antagonist medications, prescription fulfillment services, and generic drug supply agreements, indicating a disconnect between UNSPSC taxonomy and how these jurisdictions actually tag pharmaceutical purchases.

The geographic spread includes Florida, Texas, and Minnesota, with the most substantive recent activity centered on multi-state cooperative purchasing. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 drug deactivation systems annually through competitive bidding, with a July 26, 2023 response deadline and quarterly deliveries to the Seminole County Community Health Building. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. Most significantly, the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in multiple jurisdictions including Oregon, with proposals due March 26, 2026 and contract awards effective July 1, 2026. The code shows minimal relevant recent activity—the three posted opportunities address distinct pharmaceutical services that do not meaningfully represent belladonna or opium procurement.